

Human Activin RIIB Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: AF339

DESCRIPTION			
Species Reactivity	Human		
Specificity	Detects human Activin RIIB in direct ELISAs and Western blots. In direct ELISAs, approximately 50% cross-reactivity with recombinant mouse Activin RIIB is observed, and less than 1% cross-reactivity with recombinant human (rh) Activin RIIA, rhActivin RIA, and rhActivin RIB is observed.		
Source	Polyclonal Goat IgG		
Purification	Antigen Affinity-purified		
Immunogen	Mouse myeloma cell line NS0-derived recombinant human Activin RIIB Ser19-Thr134 Accession # CAA54671		
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method.		
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.		


APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Western Blot	0.1 μg/mL	Recombinant Human Activin RIIB Fc Chimera (Catalog # 339-RB)
Immunohistochemistry	5-15 μg/mL	See Below
Blockade of Receptor-ligand Interaction	Biotinylated Human/N	s, 1-3 µg/mL of this antibody will block 50% of the binding of 30 ng/mL of Recombinant Mouse/Rat Activin A to immobilized Recombinant Human Activin RIIB Fc Chimera (Catalog # ug/mL (100 uL/well). At 30 µg/mL, this antibody will block >90% of the binding.

DATA

Immunohistochemistry



Activin RIIB in Human Placenta. Activin RIIB was detected in immersion fixed paraffin-embedded sections of human placenta (cross-section of chorionic villi) using 5 µg/mL Goat Anti-Human Activin RIIB Antigen Affinity-purified Polyclonal Antibody (Catalog # AF339) overnight at 4 °C. Tissue was stained with the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

PREPARATION AND STORAGE	

Reconstitution Reconstitute at 0.2 mg/mL in sterile PBS.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

*Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Rev. 2/6/2018 Page 1 of 2





Human Activin RIIB Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: AF339

BACKGROUND

Activin isoforms and other members of the TGF-β superfamily exert their biological effects by binding to heteromeric complexes of a type I and a type II serine-threonine kinase receptor, both of which are essential for signal transduction. Seven type I and five type II receptors, including the two type I and the two type II activin receptors, designated ActR-I(A), ActR-IB, ActR-II(A) and ActR-IIB, have been cloned from mammals. Through alternative mRNA splicing, multiple ActR-IIB isoforms can also be generated, adding to the complexity of the activin receptor system. Different activin isoforms bind with different high-affinities to the various type II isoforms. Type I activin receptors do not bind directly to activin, but will associate with the type II receptor-activin complex and initiate signal transduction. Besides the activin isoforms, ActR-II will also bind inhibin, BMP-2 and BMP-7 with lower affinities. ActR-I can also bind and form signaling complexes with the BMP-2/7-bound BMPR-II. Activin type II receptors are highly conserved. Human, mouse and rat type II activin receptors share greater than 98% amino acid sequence homology. Recombinant soluble activin type II receptors bind activin with high affinity, and are potent activin antagonists.

References:

- 1. Attisano, L. et al. (1996) Mol. and Cell Biol. 16:1066.
- 2. Woodruff, T.K. (1998) Biochem. Pharmacology 55:953.

Rev. 2/6/2018 Page 2 of 2

